Provectus Biopharmaceuticals Stock Number Of Shares Shorted
| PVCT Stock | USD 0.07 0.0004 0.56% |
Provectus Biopharmaceutica's fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Provectus OTC Stock price.
Provectus |
Provectus Biopharmaceuticals OTC Stock Number Of Shares Shorted Analysis
Provectus Biopharmaceutica's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Provectus Biopharmaceutica Number Of Shares Shorted | 1.82 M |
Most of Provectus Biopharmaceutica's fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Provectus Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Provectus Biopharmaceuticals has 1.82 M of outstending shares currently sold short by investors. This is 43.06% lower than that of the Pharmaceuticals sector and 64.26% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 61.28% higher than that of the company.
Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
Provectus Fundamentals
| Return On Asset | -1.85 | |||
| Operating Margin | (4.77) % | |||
| Current Valuation | 46.73 M | |||
| Shares Outstanding | 419.55 M | |||
| Shares Owned By Insiders | 3.69 % | |||
| Shares Owned By Institutions | 0.04 % | |||
| Number Of Shares Shorted | 1.82 M | |||
| Price To Earning | (0.48) X | |||
| Price To Book | 5.44 X | |||
| Price To Sales | 55.94 X | |||
| EBITDA | (4.56 M) | |||
| Net Income | (5.54 M) | |||
| Cash And Equivalents | 84.27 K | |||
| Total Debt | 2.29 M | |||
| Debt To Equity | 0.25 % | |||
| Current Ratio | 0.27 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (1.01 M) | |||
| Short Ratio | 0.47 X | |||
| Earnings Per Share | (0.01) X | |||
| Target Price | 3.5 | |||
| Beta | 0.5 | |||
| Market Capitalization | 44.47 M | |||
| Total Asset | 3.51 M | |||
| Retained Earnings | (180.8 M) | |||
| Working Capital | 10.6 M | |||
| Current Asset | 14.72 M | |||
| Current Liabilities | 4.12 M | |||
| Z Score | -59.7 | |||
| Net Asset | 3.51 M |
About Provectus Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Provectus Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Provectus Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Provectus Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Provectus OTC Stock Analysis
When running Provectus Biopharmaceutica's price analysis, check to measure Provectus Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Provectus Biopharmaceutica is operating at the current time. Most of Provectus Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Provectus Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Provectus Biopharmaceutica's price. Additionally, you may evaluate how the addition of Provectus Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.